GlassScriptPhysician profile
Mark O Sanders
NPI 1760417547
$13,606.48
in general payments reported to CMS, 2019-2025
66 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $2,004 · 2021: $2,380 · 2022: $1,916 · 2023: $1,878 · 2024: $2,054 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,913 · Travel and Lodging: $564 · Education: $91.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.36 |
| Travel and Lodging | $564.30 |
| Education | $91.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,288.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,286.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Paragon 28, INC. | $789.77 | 2023-2024 | Trauma, Monkey Rings |
| Lilly USA, LLC | $746.48 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $740.01 | 2019-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $703.40 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $619.79 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $613.18 | 2021-2023 | |
| Pfizer INC. | $593.80 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $576.69 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $479.48 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $422.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $383.65 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $363.72 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $346.35 | 2024-2025 | Zenpep |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.